Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Drake

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Urology|April 16, 2013
Editorial commentCharles Drake
The Johns Hopkins Medical Letter Health After 50|September 21, 2010
Consultation corner. Prostate cancer vaccine offers new directionCharles Drake
The Journal of Experimental Medicine|February 15, 2012
Immunotherapy earns its spot in the ranks of cancer therapyDrew Pardoll, Charles Drake
Bioinformatics (Oxford, England)|February 13, 2004
Non-parametric, hypothesis-based analysis of microarrays for comparison of several phenotypesJeanne Kowalski, Charles Drake, Ronald H Schwartz, et al.
The Prostate|May 7, 2019
An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune responseOliver Rogers, Hung Yen, Anna Solomon, et al.
Cancer Journal (Sudbury, Mass.)|August 8, 2014
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancerLauren C Harshman, Toni K Choueiri, Charles Drake, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 16, 2018
Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I InterferonsJames T Gordy, Kun Luo, Brian Francica, et al.
Cancer Cell|February 3, 2009
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironmentMarcin Kortylewski, Hong Xin, Maciej Kujawski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2010
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized studyDaniel Keizman, Marianna Zahurak, Victoria Sinibaldi, et al.
Urology|October 17, 2017
Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical CystectomyDennis Robins, Justin Matulay, Michael Lipsky, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Urology|April 16, 2013
Editorial commentCharles Drake
The Johns Hopkins Medical Letter Health After 50|September 21, 2010
Consultation corner. Prostate cancer vaccine offers new directionCharles Drake
The Journal of Experimental Medicine|February 15, 2012
Immunotherapy earns its spot in the ranks of cancer therapyDrew Pardoll, Charles Drake
Bioinformatics (Oxford, England)|February 13, 2004
Non-parametric, hypothesis-based analysis of microarrays for comparison of several phenotypesJeanne Kowalski, Charles Drake, Ronald H Schwartz, et al.
The Prostate|May 7, 2019
An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune responseOliver Rogers, Hung Yen, Anna Solomon, et al.
Cancer Journal (Sudbury, Mass.)|August 8, 2014
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancerLauren C Harshman, Toni K Choueiri, Charles Drake, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 16, 2018
Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I InterferonsJames T Gordy, Kun Luo, Brian Francica, et al.
Cancer Cell|February 3, 2009
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironmentMarcin Kortylewski, Hong Xin, Maciej Kujawski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2010
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized studyDaniel Keizman, Marianna Zahurak, Victoria Sinibaldi, et al.
Urology|October 17, 2017
Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical CystectomyDennis Robins, Justin Matulay, Michael Lipsky, et al.
Pageof 3